Loading
ACR-6840 is an experimental small molecule from Acrivon Therapeutics, in preclinical development for cancer.
ACR-6840 is a small molecule from Acrivon Therapeutics. An inhibitor of CDK11 from Acrivon's AP3-driven cell-cycle programme. Its furthest stage is preclinical development, for cancer. No clinical trial naming it is registered on ClinicalTrials.gov. IND-enabling studies; IND filing for ACR-6840 'or alternative CDK11 inhibitor candidate' planned for the first half of 2027 (Q1 2026 results release, 13 May 2026). The 12 August 2026 release no longer names ACR-6840 and refers to an 'Internally-discovered development candidate'. It has not been shown to work in people.
An inhibitor of CDK11 from Acrivon's AP3-driven cell-cycle programme. Connects to CDK11.
1.ACR-6840 slips into a pocket on CDK11.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"ACR-6840" OR ABSTRACT:"ACR-6840") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ACR-6840, not a curated reading list.
Shares Acrivon Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Acrivon Therapeutics and the tag pipeline.
Shares Acrivon Therapeutics and the tag pipeline.
Shares Acrivon Therapeutics and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/